ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "NTRK Fusions"
Episode Synopsis
Identification of molecular alterations in NTRK 1-3 has become increasingly important with the emergence of histology-agnostic, US Food and Drug Administration-approved, effective inhibitors. The host discusses with Dr. Jaclyn Hechtman, director of clinical diagnostic development at Neogenomics, her practical insights on how testing for NTRK fusion can best be implemented and communicated within the multidisciplinary healthcare team.
More episodes of the podcast Springer Nature
Resisting parasitoids: beetle v wasp
26/11/2025
The consequences of invasion
29/10/2025
Older and wiser? The neural correlates of worry induction and reappraisal in older adults
27/10/2025
Genomic responses to past and future change
27/08/2025
July 2025: ECI Katie Strobel
20/08/2025
Colourful signals in Anolis lizards
30/07/2025
In God we trust